Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study is for subjects with a B-cell lymphoid malignancy (lymphoma) or chronic
lymphocytic leukemia (CLL) that has come back after or did not get better with previous
treatment. The purpose of this study is to find out the highest dose of lenalidomide that can
be given together with bendamustine and rituximab. The study will also look what effects the
combination of lenalidomide and bendamustine and the combination of lenalidomide,
bendamustine and rituximab will have on patients and their disease.